Abstract
This study was carried out to estimate how platelet aggregation might take a part in pathogenesis of diabetic vascular disease. 296 subjects were chosen in our diabetic clinic and examined platelet aggregation induced by two concentration's ADP solution (high concentration: 2μmol/L, low: 0.4μmol/L) with two channel aggregometer. Aggregation curves were divided into four type according to presence or absence of second wave of aggregation.
1) Patients with retinopathy in degree of Scott I-II were observed to have no significant difference compared with age-sex mached diabetic controls. But an eases with retinopathy in degree of Scott III, IV and V significant hyper-platelet aggregation was recognized. Thus, platelet hyperfunction was thought to be a risk factor to proliferative retinopathy.
2) Relationship between platelet aggregation and duration of diabetes was studied. In proliferative retinopathy, diabetes with duration of more than 10 years had higher frequency of hyper-platelet aggregation patterns than below 5 years duration.
3) Platelet aggregation was changeable in three kinds of antidiabetic therapy. Hyper-aggregation patterns appeared to remain in 52.4% of diet therapy group and in 43% of insulin therapy group. But oral antidiabetic therapy group had 66.6% with hyper-aggregation patterns than the others.
4) Aspirin was given as correcting agent to hyper-platelet aggregation to diabetics with ordinarily diabetic therapy. The effect of aspirin on platelet aggregation was difference according to the kinds of antidiabetic therapy. The improvement of hyperfunction was significant in diet and insulin therapy groups. But significant improvement was not obtained in diabetes with oral antidiabetic therapy.
It is suggested that platelet aggregation of diabetes was much influenced by duration of diabetes, degree and severity of retinopathy and kinds of diabetic therapy. And aspirin had not shown the same effect on the improvement of platelet aggregation of all diabetes.
